Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2008 | Original Article

Chronic ACE inhibitor treatment increases angiotensin type 1 receptor binding in vivo in the dog kidney

Authors: Tamas G. Zober, Maria Elena Fabucci, Wei Zheng, Phillip R. Brown, Esen Seckin, William B. Mathews, Kathryn Sandberg, Zsolt Szabo

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2008

Abstract

Purpose

PET imaging has been recently introduced for investigating the type 1 angiotensin II receptor (AT₁R) in vivo. The goal of the present study was to investigate the effects of acute and chronic exposure to angiotensin converting enzyme inhibitors (ACEI) on the AT₁R in the dog kidney.

Methods

Animals were imaged at baseline, after acute intravenous ACEI treatment and after a chronic 2-week exposure to an oral ACEI. Control animals were imaged at identical time points in the absence of ACEI treatment.

Results

In vivo AT₁R binding expressed by K _i was increased in the renal cortex by chronic ACEI treatment (p < 0.05). In vitro measurements of AT₁R density (B _max) also revealed significant increases in AT₁R in isolated glomeruli (p < 0.05). Plasma renin activity was increased, but angiotensin II (Ang II) and the Ang II/Ang I ratio showed a weak correlation with chronic ACEI treatment, consistent with an Ang II escape phenomenon.

Conclusion

This study reveals, for the first time, that chronic ACEI treatment increases AT₁R binding in vivo in the dog renal cortex.

Owonikoko TK, Fabucci ME, Brown PR, Nisar N, Hilton J, Mathews WB, et al. In vivo investigation of estrogen regulation of adrenal and renal angiotensin AT₁ receptor expression by PET. J Nucl Med. 2003;45:94–100.

Szabo Z, Speth RC, Brown PR, Kerenyi L, Kao PF, Mathews WB, et al. Use of positron emission tomography to study AT₁ receptor regulation in vivo. J Am Soc Nephrol. 2001;12:1350–8.PubMed

Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.PubMedCrossRef

Hamill TG, Burns HD, Dannals RF, Mathews WB, Musachio JL, Ravert HT, et al. Development of [¹¹C]L-159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging. Appl Radiat Isotopes. 1996;47:211–8.CrossRef

Kim SE, Scheffel U, Szabo Z, Burns HD, Gibson RE, Ravert HT, et al. In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist. J Nucl Med. 1996;37:307–11.PubMed

Szabo Z, Kao PF, Burns HD, Gibson RE, Hamill TG, Ravert HT, et al. Investigation of angiotensin II/AT₁ receptors with carbon-11-L-159,884: a selective AT₁ antagonist. J Nucl Med. 1998;39:1209–13.PubMed

Naitoh M, Suzuki H, Arakawa K, Matsumoto A, Ichihara A, Matsuda H, et al. Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension. Am J Physiol. 1997;272:H679–87.PubMed

Gjedde A. Calculation of glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 1982;4:237–74.CrossRef

Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7.PubMed

10.

Carson RE. Mathematical modeling and compartmental analysis. In: Harbert JC, Eckelman WC, Neumann RD, editors. Nuclear medicine diagnosis and therapy. New York: Thieme; 1996. p. 167–93.

11.

Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627–30.PubMedCrossRef

12.

Mok KY, Sandberg K, Sweeny JM, Zheng W, Lee S, Mulroney SE. Growth hormone regulation of glomerular AT₁ angiotensin receptors in adult uninephrectomized male rats. Am J Physiol Renal Physiol 2003;285:F1085–91.PubMed

13.

Roesch DM, Tian Y, Zheng W, Shi M, Verbalis JG, Sandberg K. Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats. Endocrinology. 2000;141:4629–36.PubMedCrossRef

14.

Abdi H. Factor rotations. In: Lewis-Beck M, Bryman A, Futing T, editors. Encyclopedia for research methods for social sciences. Thousand Oaks: Sage; 2003. p. 978–82.

15.

Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000;20:423–51.PubMedCrossRef

16.

Wong DF, Singer HS, Brandt J, Shaya E, Chen C, Brown J, et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med. 1997;38:1243–7.PubMed

17.

Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL, et al. Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [¹¹C]NMPB and PET. Synapse. 2001;39:275–7.PubMedCrossRef

18.

Szabo Z, Kao PF, Scheffel U, Suehiro M, Mathews WB, Ravert HT, et al. Positron emission tomography imaging of serotonin transporters in the human brain using [¹¹C](+)McN5652. Synapse. 1995;20:37–43.PubMedCrossRef

19.

Delforge J, Mesangeau D, Dolle F, Merlet P, Loc’h C, Bottlaender M, et al. In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. J Nucl Med. 2002;43:215–26.PubMed

20.

Kiesewetter DO, Carson RE, Jagoda EM, Herscovitch P, Eckelman WC. Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. Life Sci. 1999;64:511–8.PubMedCrossRef

21.

Aleksic S, Szabo Z, Scheffel U, Ravert HT, Mathews WB, Vaterlein O, et al. In vivo labeling of endothelin receptors with [¹¹C]L-735,037: studies in mice and a dog. J Nucl Med. 2001;42:1274–80.PubMed

22.

Szabo Z, Xia J, Mathews WB, Brown PR. Future direction of renal positron emission tomography. Sem Nucl Med. 2006;36:36–50.CrossRef

23.

Szabo Z, Mathews WB. Positron emission tomography imaging of the kidneys. In: Prigent A, Piepsz A, editors. Functional imaging in nephro-urology. London: Taylor and Francis; 2006.

24.

MacDonald JR, Susick RL Jr, Pegg DG, Dominick MA. Renal structure and function in rats after suprapharmacologic doses of quinapril, an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19:282–9.PubMedCrossRef

25.

Hamlin R, Pijpers FS, Mandigers PJ. Plasma ACE inhibition by five different ACE inhibitors. Vet Q. 1998;20(Suppl 1):S109.PubMed

26.

Navar LG, Kobori H, Prieto-Carrasquero M. Intrarenal angiotensin II and hypertension. Curr Hypertens Rep. 2003;5:135–43.PubMedCrossRef

27.

Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000;101:844–6.PubMed

28.

Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol. 2001;37:1056–61.PubMedCrossRef

29.

Funabiki K, Onishi K, Dohi K, Koji T, Imanaka-Yoshida K, Ito M, et al. Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. Am J Physiol Heart Circ Physiol. 2004;287:H2487–92.PubMedCrossRef

30.

Zober TG, Seckin E, Mathews WB, Hilton J, Yoo SE, Sandberg K, et al. Imaging the AT₁ receptor with the radioligand [11C]KR31173 and PET in mice, dogs and baboons. Nucl Med Biol. 2006;33:5–13.PubMedCrossRef

31.

Perneger TV. What’s wrong with Bonferroni adjustments. Br Med J. 1998;316:1236–8.

Title: Chronic ACE inhibitor treatment increases angiotensin type 1 receptor binding in vivo in the dog kidney
Authors: Tamas G. Zober
Maria Elena Fabucci
Wei Zheng
Phillip R. Brown
Esen Seckin
William B. Mathews
Kathryn Sandberg
Zsolt Szabo
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0667-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Chronic ACE inhibitor treatment increases angiotensin type 1 receptor binding in vivo in the dog kidney

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2008

Bronchial circulation angiogenesis in the rat quantified with SPECT and micro-CT

An imaging analysis of 99mTc-UBI (29–41) uptake in S. aureus infected thighs of rabbits on ciprofloxacin treatment

The rapid growth of multimodality imaging in Europe Multimodality (MM) imaging: Enhancement through interlacing

Can we produce an image of bacteria with radiopharmaceuticals?

Sources of attenuation-correction artefacts in cardiac PET/CT and SPECT/CT

Ictal technetium-99 m ethyl cysteinate dimer single-photon emission tomographic findings in epileptic patients with polymicrogyria syndromes: A Subtraction of ictal–interictal SPECT coregistered to MRI study